Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival BenefitMarco A. Mascarella, Umamaheswar Duvvuri, Tolani F. Olonisakin et al.|Clinical Cancer Research|2023Cited by 10
Treatment package time < 14 weeks improves recurrence free and disease specific survival in HPV positive OPC with high-risk featuresManasa Melachuri, Umamaheswar Duvvuri, Chareeni Kurukulasuriya et al.|Oral Oncology|2024Cited by 5
Abstract 1311: Feasibility of plasma ctDNA for detecting brain metastasis-specific alterations in lung cancer.Laura P. Stabile, Timothy F. Burns, Ahmed Habib et al.|Cancer Research|2026Cited by 0